Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

ANGLE Raises Further GBP1.5 Million In Share Subscription (ALLISS)

Wed, 04th Mar 2015 09:20

LONDON (Alliance News) - ANGLE PLC on Wednesday said it has raised GBP1.5 million from its shareholders via a share subscription.

ANGLE issued 2.3 million shares at 65 pence to its shareholders and said the offer was four-times oversubcribed. Shares in ANGLE were up 0.6% to 72.96 pence on Wednesday.

The money has been raised in addition to the GBP7.3 million placing and subscription Angle announced in February.

Net of expenses, the company now has raised a total of GBP8.2 million.

"We are delighted to have received such a strong level of support from our retail shareholders with the offer more than four times over-subscribed. In total we have raised GBP8.2 million net of expenses in our placing, subscription and offer, which puts ANGLE in a strong position to progress its first clinical application in ovarian cancer," said ANGLE Chief Executive Andrew Newland.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.

Related Shares

More News
5 Jun 2024 16:32

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

5 Jun 2024 10:08

Angle unveils plans to raise more than £10m

(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.